Until currently, HD-MTX therapy with repeated intrathecal injections has been generally accepted as an elective regimen for preventing central nervous system involvement and acts as a cornerstone of treatment in children with ALL (Mantadakis et al., 2005). However, high-dose methotrexate (HD-MTX), defined as a dose
Latar belakang. Angka remisi pascakemoterapi LLA masih belum memuaskan, banyak faktor yang memengaruhi belum optimalnya luaran terapi LLA, salah satunya adalah faktor subtipe sel limfosit LLA. Tujuan. Melihat hubungan subtipe sel limfosit dengan tingkat remisi pascakemoterapi fase induksi LLA. Metode. Penelitian kohort prospektif dilakukan di RS dr. Hasan Sadikin Bandung dari bulan Februari-September 2016. Subyek adalah anak <14 tahun yang baru didiagnosis LLA berdasarkan hasil aspirasi sumsum tulang. Diambil sampel darah perifer untuk dilakukan pemeriksaan immunophenotyping agar dapat diketahui subtipe sel limfositnya, dilakukan kemoterapi fase induksi selama 6 minggu berdasarkan protokol terapi. Dilakukan aspirasi sumsum tulang evaluasi untuk melihat tingkat remisinya. Analisis statistik dilakukan dengan uji Fisher-exact. Hasil. Terdapat 40 subjek yang memenuhi kriteria inklusi dan menjalani kemoterapi fase induksi. Dari 40 subjek, 26 menyelesaikan kemoterapi fase induksi, dan dari 26 subjek yang dilakukan evaluasi aspirasi sumsum tulang, 20/26 mengalami remisi lengkap dan 6/26 tidak remisi. Terdapat 18/24 subjek sel B-LLA yang mengalami remisi lengkap dan 6/24 tidak remisi, sedangkan penderita sel T-LLA yang mengalami remisi lengkap 2/2 subjek. Tidak terdapat perbedaan yang bermakna antara subtipe sel limfosit dengan tingkat remisi pascakemoterapi fase induksi (p=0,585). Kesimpulan. Subtipe sel limfosit tidak berpengaruh terhadap tingkat remisi pascakemoterapi fase induksi. Sari Pediatri 2017;18(6):448-52Kata kunci: LLA, remisi lengkap fase induksi, subtipe sel limfosit Correlation of Lymphocyte Cell Subtype with Remission after Induction Phase Chemotherapy in Acute Lymphoblastic LeukemiaNur Suryawan, Ponpon Idjradinata, Lelani Reniarti Background. The remission rate after chemotherapy is still unsatisfactory. Many factors cause the outcome of the therapy not optimally, one of which is the lymphocyte cell subtype of the patient. Objective. To find out the correlation of lymphocyte cell subtype with remission after induction phase chemotherapy in ALL. Methods. This prospective cohort study was done in the in-patient ward of Child Heakth Department, Hasan Sadikin Hospital during February-September 2016. The subject were <14 years old children, newly diagnosed as ALL children according to the bone marrow aspiration. Peripheral blood sample were taken for immunophenotyping examination for lymphocyte cell subtype. Based on the therapy protocol, induction phase chemotherapy was done for 6 weeks, and afterwards bone marrow aspiration was done again to find out the remission grade. Statistical analysis using Fisher-exact test.Results. There were 40 subjects who fulfilled the inclusion criteria and had the induction phase chemotherapy. Only 26 of 40 subjects completed the induction phase chemotherapy, and of the 26 subjects who had bone marrow aspiration, 20/26 got complete remission; 6/26 got no remission. Of 24 subjects in this study, 18/24 with B-ALL cell had completed remission, and 6/24 got no remission, while 2/...
Introduction Most pediatric cancer patients in developing countries present at an advanced stage due to delayed diagnosis, being an important barrier to effective care. The objective of this study was to evaluate the associated factor of patient delay and explore significant parental practice‐associated risk factor to patient delay. Methods This was a sequential mixed methodology, utilizing data from the Indonesian Pediatric Cancer Registry for clinical variables and completed interviews with parents using structured questionnaires to obtain their sociodemographic data. A binary logistic regression analysis model was fitted to identify factors associated with patient delay. Additional semi‐structured interviews related to parental practice of using complementary and alternative medicine (CAM) were administered to 30 parents. Thematic framework analysis was performed on qualitative data to explore determinant factors of parental practice of using CAM. Results We interviewed 356 parents with children with cancer. The median patient delay was 14 days (interquartile range [IQR]: 6–46.5 days). The most extended delay was in patients with malignant bone tumors (median 66, IQR: 14–126). In multivariable logistic regression analysis, solid cancer (odds ratio [OR] = 5.22, 95% confidence interval [CI]: 2.79–9.77, p < .001) and use of CAM (OR = 1.86, 95% CI: 1.13–3.08, p = .015) were associated with patient delay. Qualitative interviews highlighted key issues relative to determinant parental factors using CAM, including vague initial childhood cancer symptoms, parental health‐seeking behavior, CAM availability and accessibility, also barriers of healthcare facilities. Conclusion Type of cancer and use of CAM are essential factors that cause patient delay. It should be addressed in the future childhood cancer awareness and childhood cancer diagnosis pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.